Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Paul Strijbos"'
Autor:
Seya Colloud, Thomas Metcalfe, Scott Askin, Shibeshih Belachew, Johannes Ammann, Ernst Bos, Timothy Kilchenmann, Paul Strijbos, Damien Eggenspieler, Laurent Servais, Chloé Garay, Athanasios Konstantakopoulos, Armin Ritzhaupt, Thorsten Vetter, Claudia Vincenzi, Francesca Cerreta
Publikováno v:
npj Digital Medicine, Vol 6, Iss 1, Pp 1-11 (2023)
Abstract Digital health technology tools (DHTTs) present real opportunities for accelerating innovation, improving patient care, reducing clinical trial duration and minimising risk in medicines development. This review is comprised of four case stud
Externí odkaz:
https://doaj.org/article/96809dd19189420b9cbff01bd079ea62
Autor:
Laurent Servais, Eric Camino, Aude Clement, Craig M. McDonald, Jacek Lukawy, Linda P. Lowes, Damien Eggenspieler, Francesca Cerreta, Paul Strijbos
Publikováno v:
Digital Biomarkers, Vol 5, Iss 2, Pp 183-190 (2021)
Background: Functional outcome measures used to assess efficacy in clinical trials of investigational treatments for rare neuromuscular diseases like Duchenne muscular dystrophy (DMD) are performance-based tasks completed by the patient during hospit
Externí odkaz:
https://doaj.org/article/6d035a7c14754f65a79ab743a9237e5f
Publikováno v:
Journal of Neuromuscular Diseases. 9:335-346
In 2019, stride velocity 95th centile (SV95C) became the first wearable-derived digital clinical outcome assessment (COA) qualified by the European Medicines Agency (EMA) for use as a secondary endpoint in trials for Duchenne muscular dystrophy. SV95
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71cc937a58ae1e58e6425be5dd0da700
https://doi.org/10.3233/jnd-210743
https://doi.org/10.3233/jnd-210743
Autor:
Eric Camino, Jacek Lukawy, Laurent Servais, Aude Clement, Paul Strijbos, Craig M. McDonald, Damien Eggenspieler, Francesca Cerreta, Linda Lowes
Publikováno v:
Digital Biomarkers, Vol 5, Iss 2, Pp 183-190 (2021)
Digit Biomark
Digit Biomark
Background: Functional outcome measures used to assess efficacy in clinical trials of investigational treatments for rare neuromuscular diseases like Duchenne muscular dystrophy (DMD) are performance-based tasks completed by the patient during hospit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65f79f64c1e51308ac4a595073d623ff
https://www.karger.com/Article/FullText/517411
https://www.karger.com/Article/FullText/517411